Navigation Links
The economic cost of advanced liver disease
Date:11/7/2011

Health care costs for hepatitis C patients with end-stage liver disease are nearly 2.5 times higher than those in the early stages, according to a Henry Ford Hospital study.

Although infection with the hepatitis C virus increases health care costs overall, the specific impact of the disease's progressive severity on health care costs has previously not been well studied.

"The severity of hepatitis C-related liver disease increases with age, and the aging hepatitis C population is likely to increase the economic burden of the infection on our health care system," says Stuart C. Gordon, M.D., director of Hepatology at Henry Ford Hospital and lead author of the study.

The results of the study will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco this week.

It is estimated that the majority of the four million Americans with chronic hepatitis C virus infection remain undiagnosed and thus untreated. The increasing disease prevalence has created an aging population of patients with chronic hepatitis C infection and a resultant increase in the number of patients with cirrhosis, and, subsequently, the complications of cirrhosis (end-stage liver disease).

The Henry Ford study compared the economic burden for U.S. patients with chronic hepatitis C stratified by severity of liver disease in a large private health insurance claims database from 2003 to 2010. The database included claims for all prescription medications and all medical services submitted for payment.

Researchers looked at 53,796 patients with chronic hepatitis C: 41,858 (78%) without cirrhosis, 3,718 (7%) with compensated cirrhosis, and 8,220 (15%) with end-stage liver disease. Mean age was 49 years, 51 years, and 52 years respectively.

Mean health care costs (per month) were 32% and 247% higher for patients with compensated cirrhosis ($1,870) and end-stage liver disease ($4,931), compared to those without cirrhosis ($1,420) and these results were independent of age.

A similar trend is apparent for mean hepatitis C-related health care costs. Overall, 56% of total costs were hepatitis C-related and this proportion increased with disease severity (46%, 57%, and 71% for patients without cirrhosis, compensated cirrhosis, and end-stage liver disease, respectively).

Pharmacy, ambulatory, and inpatient care accounted for 90% of costs for hepatitis C patients without cirrhosis and 93% of the costs for those with compensated cirrhosis and end-stage liver disease.

The study estimated the annual health care costs to be $24,176 for patients with chronic hepatitis C infection. When looked at by disease stage, average annual costs were estimated to be $17,277 among patients with no cirrhosis, $22,752 among patients with compensated cirrhosis, and $59,995 annually among patients with end-stage liver disease.

Dr. Gordon indicated that the primary drivers of higher health care expenses were found to be inpatient costs for patients with end-stage liver disease and pharmacy costs for patients with compensated cirrhosis.

"As we see patients with more advanced liver disease, we see significantly more costs to the system. The key, therefore, is to treat and cure the infection early to prevent the consequences of more advanced disease and the associated economic burden," says Dr. Gordon.

Current treatment for hepatitis C involves a cocktail of three drugs taken for 24-48 weeks with viral clearance "cure" rates of 65-80 percent.

Most people who are infected with hepatitis C remain without symptoms for years. The infection may lead to scarring of the liver (cirrhosis), liver cancer, the need for liver transplant, and potentially death


'/>"/>
Contact: Maria Seyrig
mseyrig1@hfhs.org
313-874-4039
Henry Ford Health System
Source:Eurekalert

Related medicine news :

1. Decrease in observed rate of TB at a time of economic recession
2. Increased use of bikes for commuting offers economic, health benefits
3. Public lecture to explore intersection of economics, human behavior, and brain science
4. Lower socioeconomic status linked with heart disease despite improvements in other risk factor
5. Bad Economic News Taking Toll on Americans Emotions
6. New report shows seniors economic security falling
7. Socioeconomic status as child dictates response to stress as adult
8. Economic factors associated with increase in closures of emergency departments
9. Autism Takes an Economic Toll on Moms Job, Income: Study
10. Socioeconomic status influences celiac disease diagnosis
11. Study: Socioeconomics playing reduced role in autism diagnoses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any ... useful, properly analyzed data. The team at Beckman Coulter has designed Kaluza, templates with ... speed' and the need to operate in a GLP (Good Laboratory Practice) fashion. , ...
(Date:12/7/2016)... ... , ... When it came time to blow out his candles on his 14th birthday, Estefano ... Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family with a phone ... transplant recipient. , “He was playing at home, when we got the phone call ...
(Date:12/7/2016)... ... December 07, 2016 , ... One of two inventors from ... securement tape is painful for her. "This is why the co-inventor and I have ... said. , They then created a prototype of the patent-pending AV-AIR, a device that ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... announce that its fully redesigned website, which launched October 17, 2016, features comprehensive ... responsive design and easy-to-navigate layout. Visitors and patients can discover the latest clinical ...
(Date:12/7/2016)... Studio City, CA (PRWEB) , ... December 07, 2016 , ... ... number during the holidays and winter seasons. One major study analyzing heart attacks ... January compared to August of a given year. We would all agree of course–no ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) ... subsidiaries—American Homecare Federation, At-Home IV Infusion Professional, BioRx, MedPro Rx, and ... infusion services, visit diplomat.is/specialty-infusion .  ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, ... "As we continue to build on ...
(Date:12/7/2016)... ZIONA SCIENCE PARK , Israel ... company Kadimastem (TASE: KDST) announced today the signing of a memorandum ... between the companies. The synergy between the companies will assist in ... as a worldwide leader in innovative treatment for severe diseases in ... ...
(Date:12/7/2016)... -- Based on its recent analysis of the ... recognizes Nemaura Pharma Limited with the 2016 ... Technology Leadership. Nemaura Pharma,s transdermal drug delivery ... delivery technologies, especially in delivering biologics. Its ... Memspatch and Micropatch respectively, facilitate minimally painful ...
Breaking Medicine Technology: